David Risinger

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers....

Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate. The Pfizer Analysts: Morgan Stanley analyst David Risinger has an Equal-weight rating on Pfizer with a $42 price target.  SVB Leerink analyst Geoffrey Porges...

Eli Lilly And Co (NYSE: LLY) stock has pulled back in recent months, rendering its valuation more attractive, according to a Morgan Stanley analyst.  The Lilly Analyst: David Risinger upgraded Eli Lilly from Equal-weight to Overweight and increased the price target from $157 to $176. The...

Despite the pandemic risk, one analyst at Morgan Stanley remains bullish on AbbVie Inc (NYSE: ABBV). The AbbVie Analyst David Risinger maintained an Overweight on AbbVie with a $95 price target.  The AbbVie Thesis Risks to U.S. sales stemming from unemployment and the Humira patent cliff...

Eli Lilly And Co (NYSE: LLY) stock has outperformed its big pharma peers, prompting an analyst at Morgan Stanley to turn cautious on the stock. The Lilly Analyst David Risinger downgraded shares of Lilly from Overweight to Equal-weight and maintained a $148 price target. The Lilly Thesis Lilly...

While Elanco Animal Health Inc’s (NYSE: ELAN) current valuation reflects the ongoing investor concerns, the focus is now likely to shift to the positives related to the Bayer transaction, prospects of margin expansion and long-term pipeline potential over 20202, according to Morgan Stanley....

Morgan Stanley downgraded Pfizer Inc (NYSE: PFE) Tuesday after the drug company announced the spinoff of its Upjohn division on Monday, sending its stock downward. Shares of Mylan NV (NASDAQ: MYL), which merged with Upjohn, were moving in the other direction. The Analyst...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are down 66.1% in the past year on fears about the negative impact of opioid litigation. A series of unusually large options trades Monday morning suggests at least one large trader thinks Teva has even more downside ahead. The Trades On Monday...

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley analyst David Risinger made the following changes to his pharma stock coverage: Endo...

Allergan plc (NYSE: AGN) needs new drivers for revenue growth, according to Morgan Stanley. Although the drugmaker's stock is inexpensive, pipeline and growth uncertainties will continue to exert pressure, the sell-side firm said in a downgrade note. The Analyst Morgan Stanley’s David...

AbbVie Inc (NYSE: ABBV) dropped Friday after falling short of fourth-quarter earnings estimates. A $1.90 bottom line missed a $1.93 estimate, and sales of $8.305 billion underperformed forecasts of $8.37 billion. The Analysts Morgan Stanley analyst David Risinger maintained an Equal-weight rating...

Bausch Health Companies Inc (NYSE: BHC), formerly Valeant Pharma, holds upside potential of about 32 percent, according to Morgan Stanley. The Analyst Analyst David Risinger upgraded Bausch from Equal-weight to Overweight and set $32 price target.  The Thesis Bausch's growth is expected...

Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. generic business, and certain product divestments. Non-GAAP income fell a less-than-expected to 68...

Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL) suffers from “uncertain prospects” that warrant a neutral stance, according to Morgan Stanley.  The Rating Analyst David Risinger downgraded Mylan from Overweight to Equal-weight and cut the price target from $46...

Amneal Pharmaceuticals (NYSE: AMRX) announced Monday the FDA approval of its newest drug, a generic version of Potassium Chloride oral solution. The Analysts Morgan Stanley analyst David Risinger initiated coverage with an Overweight rating for Amneal Pharmaceuticals, with a price target of $22....